Bjorn R Olsen

US Patent:

6899915, May 31, 2005

Filed:

Nov 29, 2001

Appl. No.:

09/997734

Inventors:

Pamela C. Yelick - Concord MA, US
John D. Bartlett - Acton MA, US
Joseph P. Vacanti - Winchester MA, US
Bjorn R. Olsen - Milton MA, US
Phillip Stashenko - Medfield MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA
General Hospital Corporation - Boston MA
Forsyth Dental Infirmary for Children, Inc. - Boston MA

International Classification:

A61C013/08

US Classification:

427 226, 4332021, 433204, 264 19, 523115

Abstract:

Tooth tissues include the pulp mesenchyme that forms the dentin and an epithelium that is responsible for enamel formation. Cells from these tissues were obtained from porcine third molars and were seeded onto a biodegradable scaffold composed of a polyglycolic acid—polylactic acid copolymer. Cell polymer constructs were then surgically implanted into the omentum of athymic nude rats so that the constructs would have a blood supply and these tissues were allowed to develop inside the rats. Infrequently, columnar epithelial cells were observed as a single layer on the outside of the dentin-like matrix similar to the actual arrangement of ameloblasts over dentin during early tooth development. Developing tooth tissues derived from such cell polymer constructs could eventually be surgically implanted into the gum of an edentulous recipient where the construct would receive a blood supply and develop to maturity, providing the recipient with a biological tooth replacement.

US Patent:

7462447, Dec 9, 2008

Filed:

Feb 1, 2002

Appl. No.:

10/467033

Inventors:

Valdenize Tiziani - Fortaleza CE, BR
Ernst Reichenberger - West Hartford CT, US
Yasuyoshi Ueki - Needham MA, US
Bjorn R. Olsen - Milton MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C12P 1/68
C12P 19/34
C12N 9/00
C07H 21/04
C07K 1/00

US Classification:

435 6, 435 912, 435183, 536 231, 536 2431, 536 2433, 530350

Abstract:

The invention provides mutant SH3-binding protein (SH3BP2) nucleic acids, polypeptides, and agents which selectively bind to the mutant SH3BP2 molecules and which do not bind to the wild type SH3BP2 molecules. Methods for selecting agents which inhibit mutant SH3BP2 expression, as well as diagnostic and therapeutic methods which utilize the mutant SH3BP2 molecules for diagnosing and treating disorders of bone homeostasis, also are provided.

US Patent:

20030027151, Feb 6, 2003

Filed:

Aug 17, 2001

Appl. No.:

09/931375

Inventors:

Matthew Warman - Shaker Heights OH, US
Yaoqin Gong - Jinan, CN
Bjorn Olsen - Milton MA, US
Georges Rawadi - Paris, FR
Sergio Roman-Roman - Paris, FR

International Classification:

C12Q001/68
C07H021/04

US Classification:

435/006000, 536/023200

Abstract:

A bone strength and mineralization regulatory (“BSMR”) protein is provided that can exist in multiple forms and that affects bone density. Polymorphic gene sequences of the protein are provided that are diagnostic of predipostion to osteoporosis. Other detection tools, compositions and methods of their use also are provided for predicting, evaluating and altering bone strength and mineralization status. The invention provides new natural and synthetic pharmaceuticals that effect the BSMR regulatory pathway and improve bone status. Tools also are provided for finding new pharmaceuticals that operate by binding to BSMR and that activate and/or deactivate this protein's biological function related to osteoporosis and blood vessel formation.

US Patent:

20040219489, Nov 4, 2004

Filed:

Jun 3, 2004

Appl. No.:

10/859896

Inventors:

Pamela Yelick - Concord MA, US
John Bartlett - Acton MA, US
Joseph Vacanti - Winchester MA, US
Bjorn Olsen - Milton MA, US
Phillip Stashenko - Medfield MA, US

International Classification:

A61C013/08

US Classification:

433/202100, 433/204000

Abstract:

Tooth tissues include the pulp mesenchyme that forms the dentin and an epithelium that is responsible for enamel formation. Cells from these tissues were obtained from porcine third molars and were seeded onto a biodegradable scaffold composed of a polyglycolic acid-polylactic acid copolymer. Cell polymer constructs were then surgically implanted into the omentum of athymic nude rats so that the constructs would have a blood supply and these tissues were allowed to develop inside the rats. Histological analysis of 7.5 week-old implants revealed a dentin-like collagenous matrix containing hydroxyapatite mineral surrounding a core of mesenchymal cells that appeared analogous to pulp tissue. Infrequently, columnar epithelial cells were observed as a single layer on the outside of the dentin-like matrix similar to the actual arrangement of ameloblasts over dentin during early tooth development. Developing tooth tissues derived from such cell polymer constructs could eventually be surgically implanted into the gum of an edentulous recipient where the construct would receive a blood supply and develop to maturity, providing the recipient with a biological tooth replacement.

US Patent:

20130078718, Mar 28, 2013

Filed:

Mar 9, 2011

Appl. No.:

13/583294

Inventors:

Damian Medici - Boston MA, US
Bjorn Olsen - Milton MA, US

Assignee:

PRESIDENT AND FELLOWS OF HARVARD COLLEGE - Cambridge MA

International Classification:

C12N 5/071

US Classification:

435350, 435377, 435363, 435351, 435352, 435366

Abstract:

Disclosed herein is a method of producing multipotent cells, comprising, activating ALK2 of isolated endothelial cells in a serum starved environment, to thereby produce isolated multipotent cells. Activation can be following a threshold period of serum starvation. Activating ALK2 is by contacting the isolated endothelial cells with TGFβ-2 and/or BMP4. The isolated endothelial cells may be human, such as primary vascular, primary microvascular endothelial cells, primary human umbilical vein endothelial cells (HUVEC) or primary human cutaneous microvascular endothelial cells (HCMEC). The activation of ALK2 significantly decreases expression of VE-cadherein of the cells and/or significantly increases expression of one or more of STRO-1, FSP-1, α-SMA, N-cadherin, fibronectin (FN1), Snail (SNAI1), Slug (SNAI2), ZEB-1, SIP-1, LEF-1, Twist, CD10, CD13, CD44, CD73, CD90, CD120A, and CD124. The multipotent cells may further be used to generate other cell types such as osteoblast-like cells, chondrocyte-like cells, adipocyte-like cells, neural-like cells, and myocyte-like cells, by incubating the isolated multipotent cells in the appropriate culture conditions for a period sufficient to induce differentiation. The induced cells express TIE-2.

US Patent:

56437838, Jul 1, 1997

Filed:

Dec 1, 1993

Appl. No.:

8/159784

Inventors:

Bjorn R. Olsen - Milton MA
Suk P. Oh - Chelsea MA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C12N 500
C12P 2100
A61K 3817
C07H 1900

US Classification:

435325

Abstract:

The invention features a novel collagen, type. alpha. 1 (XVIII) collagen, and uses therefor.

US Patent:

53745159, Dec 20, 1994

Filed:

Nov 13, 1992

Appl. No.:

7/974740

Inventors:

Nancy L. Parenteau - Brookline MA
Valerie S. Mason - Littleton MA
Bjorn R. Olsen - Milton MA

Assignee:

Organogenesis, Inc. - Canton MA
The President and Fellows of Harvard College - Cambridge MA

International Classification:

A01N 102
C12N 500
A61F 214

US Classification:

435 1

Abstract:

This invention is directed to an organ equivalent of the cornea part of the eye made using tissue culturing systems. The method of constructing the cornea equivalent results in a structure analogous to the eye cornea in vivo. The cornea equivalent is an in vitro model of the eye, which can be used for transplantation or implantation in vivo or for screening compounds in vitro.

US Patent:

58276416, Oct 27, 1998

Filed:

Nov 8, 1994

Appl. No.:

8/337830

Inventors:

Nancy L. Parenteau - Brookline MA
Valerie Susan Mason - Littleton MA
Bjorn Reino Olsen - Milton MA

International Classification:

A01N 102
C12N 500

US Classification:

435 11

Abstract:

This invention is directed to an organ equivalent of the cornea part of the eye made using tissue culturing systems. The method of constructing the cornea equivalent results in a structure analogous to the eye cornea in vivo. The cornea equivalent is an in vitro model of the eye, which can be used for transplantation or implantation in vivo or for screening compounds in vitro. This invention is also directed to the use of endothelial cells in other tissue and organ equivalents to promote basement membrane development. The cornea equivalent comprises an inner endothelial cell layer, a middle stromal cell and collagen mixture wherein the stromal cells are derived from fibroblast cells and an external epithelial cell layer, wherein the epithelial cells are derived from corneal epithelial cells.